Skip to main content
Erschienen in: Pediatric Nephrology 4/2019

13.11.2018 | Original Article

Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome

verfasst von: Gaël Gasongo, Larry A. Greenbaum, Olivier Niel, Theresa Kwon, Marie-Alice Macher, Anne Maisin, Véronique Baudouin, Claire Dossier, Georges Deschênes, Julien Hogan

Erschienen in: Pediatric Nephrology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Bartter syndrome (BS) is a salt-wasting tubulopathy with induced expression of cyclooxygenase-2 in the macula densa, leading to increased prostaglandin production and hyperreninemia. Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently used in BS; however, there is limited information on the impact of NSAIDs at treatment initiation or the potential utility of plasma renin level to guide therapy in patients with BS.

Methods

We included 19 patients with BS treated with NSAIDs between 1994 and 2016. We assessed serum levels of renin, aldosterone, electrolytes, calcium, phosphorus, vitamin D, and intact parathyroid hormone (iPTH) before and after treatment initiation. We also recorded modifications in sodium and potassium supplements and changes in urine calcium.

Results

Median age at diagnosis was 0.9 months [IQR 0–6.9]. Seven patients had BS types 1 or 2, 12 had BS type 3 and two had no mutation identified. There was a trend towards a decrease in sodium chloride supplementation after initiation of NSAIDs. When defining response to treatment based on the normalization of plasma renin level, responders had a greater reduction in their electrolytes supplementation. NSAIDs treatment was associated with a reduction in urine calcium. Before treatment, half of the patients had elevated iPTH, but iPTH normalized following initiation of NSAIDs in all but one patient.

Conclusions

This study confirms that NSAIDs reduce urine wasting of sodium and calcium in patients with BS. Monitoring serum renin levels may be useful to identify the lowest effective dose of NSAIDs that optimizes reduction of urine electrolyte losses.
Literatur
1.
Zurück zum Zitat Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW, Oates JA, Bartter FC (1976) Bartter’s syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med 61:43–51CrossRefPubMed Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW, Oates JA, Bartter FC (1976) Bartter’s syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med 61:43–51CrossRefPubMed
2.
Zurück zum Zitat Bartter FC, Gill JR, Frolich JC, Hollifield JW, Radfar N, Keiser HR, Oates JA, Seyberth H, Taylor AA (1976) Prostaglandins are overproduced by the kidneys and mediate hyperreninemia in Bartter’s syndrome. Trans Assoc Am Phys 89:77–91PubMed Bartter FC, Gill JR, Frolich JC, Hollifield JW, Radfar N, Keiser HR, Oates JA, Seyberth H, Taylor AA (1976) Prostaglandins are overproduced by the kidneys and mediate hyperreninemia in Bartter’s syndrome. Trans Assoc Am Phys 89:77–91PubMed
3.
Zurück zum Zitat Bartter FC, Pronove P, Gill JR, Maccardle RC (1962) Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 33:811–828CrossRefPubMed Bartter FC, Pronove P, Gill JR, Maccardle RC (1962) Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 33:811–828CrossRefPubMed
4.
Zurück zum Zitat Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 13:183–188CrossRefPubMed Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 13:183–188CrossRefPubMed
5.
Zurück zum Zitat Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP (1996) Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 14:152–156CrossRefPubMed Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP (1996) Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 14:152–156CrossRefPubMed
6.
Zurück zum Zitat Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat Genet 17:171–178CrossRefPubMed Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat Genet 17:171–178CrossRefPubMed
7.
Zurück zum Zitat Birkenhäger R, Otto E, Schürmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, Antignac C, Sudbrak R, Kispert A, Hildebrandt F (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310–314CrossRefPubMed Birkenhäger R, Otto E, Schürmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, Antignac C, Sudbrak R, Kispert A, Hildebrandt F (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310–314CrossRefPubMed
8.
Zurück zum Zitat Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, Deschenes G, Bensman A, Decramer S, Cochat P, Morin D, Broux F, Caillez M, Guyot C, Novo R, Jeunemaître X, Vargas-Poussou R (2009) Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant 24:1455–1464CrossRefPubMed Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, Deschenes G, Bensman A, Decramer S, Cochat P, Morin D, Broux F, Caillez M, Guyot C, Novo R, Jeunemaître X, Vargas-Poussou R (2009) Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant 24:1455–1464CrossRefPubMed
9.
Zurück zum Zitat Zewde T, Mattson DL (2004) Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertens 1979 44:424–428 Zewde T, Mattson DL (2004) Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertens 1979 44:424–428
10.
11.
Zurück zum Zitat Craig JC, Falk MC (1996) Indomethacin for renal impairment in neonatal Bartter’s syndrome. Lancet 347:550CrossRefPubMed Craig JC, Falk MC (1996) Indomethacin for renal impairment in neonatal Bartter’s syndrome. Lancet 347:550CrossRefPubMed
12.
Zurück zum Zitat Littlewood JM, Lee MR, Meadow SR (1976) Treatment of childhood Bartter’s syndrome with indomethacin. Lancet 2:795CrossRefPubMed Littlewood JM, Lee MR, Meadow SR (1976) Treatment of childhood Bartter’s syndrome with indomethacin. Lancet 2:795CrossRefPubMed
13.
Zurück zum Zitat Verberckmoes R, van Damme BB, Clement J, Amery A, Michielsen P (1976) Bartter’s syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int 9:302–307CrossRefPubMed Verberckmoes R, van Damme BB, Clement J, Amery A, Michielsen P (1976) Bartter’s syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int 9:302–307CrossRefPubMed
14.
Zurück zum Zitat Vaisbich MH, Fujimura MD, Koch VH (2004) Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 19:858–863CrossRefPubMed Vaisbich MH, Fujimura MD, Koch VH (2004) Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 19:858–863CrossRefPubMed
15.
Zurück zum Zitat Reinalter SC, Gröne HJ, Konrad M, Seyberth HW, Klaus G (2001) Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr 139:398–406CrossRefPubMed Reinalter SC, Gröne HJ, Konrad M, Seyberth HW, Klaus G (2001) Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr 139:398–406CrossRefPubMed
17.
Zurück zum Zitat Gomaa AA, Hassan HA, Ghaneimah SA (1990) Effect of aspirin and indomethacin on the serum and urinary calcium, magnesium and phosphate. Pharmacol Res 22:59–70CrossRefPubMed Gomaa AA, Hassan HA, Ghaneimah SA (1990) Effect of aspirin and indomethacin on the serum and urinary calcium, magnesium and phosphate. Pharmacol Res 22:59–70CrossRefPubMed
18.
Zurück zum Zitat Leonhardt A, Timmermanns G, Roth B, Seyberth HW (1992) Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr 120:546–554CrossRefPubMed Leonhardt A, Timmermanns G, Roth B, Seyberth HW (1992) Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr 120:546–554CrossRefPubMed
19.
Zurück zum Zitat Goodman AD, Vagnucci AH, Hartroft PM (1969) Pathogenesis of Bartter’s syndrome. N Engl J Med 281:1435–1439CrossRefPubMed Goodman AD, Vagnucci AH, Hartroft PM (1969) Pathogenesis of Bartter’s syndrome. N Engl J Med 281:1435–1439CrossRefPubMed
21.
Zurück zum Zitat Puricelli E, Bettinelli A, Borsa N, Sironi F, Mattiello C, Tammaro F, Tedeschi S, Bianchetti MG, Italian Collaborative Group for Bartter Syndrome (2010) Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol Dial Transplant 25:2976–2981CrossRefPubMed Puricelli E, Bettinelli A, Borsa N, Sironi F, Mattiello C, Tammaro F, Tedeschi S, Bianchetti MG, Italian Collaborative Group for Bartter Syndrome (2010) Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol Dial Transplant 25:2976–2981CrossRefPubMed
22.
Zurück zum Zitat de Groot T, Lee K, Langeslag M, Xi Q, Jalink K, Bindels RJ, Hoenderop JG (2009) Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. J Am Soc Nephrol 20:1693–1704CrossRefPubMedPubMedCentral de Groot T, Lee K, Langeslag M, Xi Q, Jalink K, Bindels RJ, Hoenderop JG (2009) Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. J Am Soc Nephrol 20:1693–1704CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat van Baal J, de Jong MD, Zijlstra FJ, Willems PH, Bindels RJ (1996) Endogenously produced prostanoids stimulate calcium reabsorption in the rabbit cortical collecting system. J Physiol 497(Pt 1):229–239CrossRefPubMedPubMedCentral van Baal J, de Jong MD, Zijlstra FJ, Willems PH, Bindels RJ (1996) Endogenously produced prostanoids stimulate calcium reabsorption in the rabbit cortical collecting system. J Physiol 497(Pt 1):229–239CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Hoenderop JG, Willems PH, Bindels RJ (2000) Toward a comprehensive molecular model of active calcium reabsorption. Am J Phys Renal Phys 278:F352–F360 Hoenderop JG, Willems PH, Bindels RJ (2000) Toward a comprehensive molecular model of active calcium reabsorption. Am J Phys Renal Phys 278:F352–F360
25.
Zurück zum Zitat Rodríguez-Soriano J, Vallo A, Aguirre M (2005) Bone mineral density and bone turnover in patients with Bartter syndrome. Pediatr Nephrol 20:1120–1125CrossRefPubMed Rodríguez-Soriano J, Vallo A, Aguirre M (2005) Bone mineral density and bone turnover in patients with Bartter syndrome. Pediatr Nephrol 20:1120–1125CrossRefPubMed
26.
Zurück zum Zitat Shoemaker L, Welch TR, Bergstrom W, Abrams SA, Yergey AL, Vieira N (1993) Calcium kinetics in the hyperprostaglandin E syndrome. Pediatr Res 33:92–96CrossRefPubMed Shoemaker L, Welch TR, Bergstrom W, Abrams SA, Yergey AL, Vieira N (1993) Calcium kinetics in the hyperprostaglandin E syndrome. Pediatr Res 33:92–96CrossRefPubMed
Metadaten
Titel
Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome
verfasst von
Gaël Gasongo
Larry A. Greenbaum
Olivier Niel
Theresa Kwon
Marie-Alice Macher
Anne Maisin
Véronique Baudouin
Claire Dossier
Georges Deschênes
Julien Hogan
Publikationsdatum
13.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 4/2019
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-018-4135-8

Weitere Artikel der Ausgabe 4/2019

Pediatric Nephrology 4/2019 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.